Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 11/20 | 0.65 |
| ▸ | MEN1 | O00255 | 10/20 | 0.65 |
| ▸ | LMNA | P02545 | 7/20 | 0.65 |
| ▸ | GAA | P10253 | 7/20 | 0.65 |
| ▸ | MAPT | P10636 | 13/20 | 0.58 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.58 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20609180 | 1.00 | KMT2A (0.65) | KMT2AMEN1LMNAGAAMAPT | |
| SCHEMBL20609182 | 1.00 | KMT2A (0.65) | KMT2AMEN1LMNAGAAMAPT | |
| SCHEMBL20609230 | 0.88 | GAA (0.77) | KMT2AMEN1LMNAGAAMAPT | |
| SCHEMBL19736309 | 0.88 | GAA (0.77) | KMT2AMEN1LMNAGAAMAPT | |
| SCHEMBL20609231 | 0.88 | GAA (0.77) | KMT2AMEN1LMNAGAAMAPT | |
| SCHEMBL20609226 | 0.86 | MEN1 (0.77) | KMT2AMEN1LMNAGAAMAPT | |
| SCHEMBL19736515 | 0.86 | MEN1 (0.77) | KMT2AMEN1LMNAGAAMAPT | |
| SCHEMBL20609224 | 0.86 | MEN1 (0.77) | KMT2AMEN1LMNAGAAMAPT | |
| SCHEMBL20609238 | 0.84 | KMT2A (0.62) | KMT2AMEN1LMNAGAAMAPT | |
| SCHEMBL20609239 | 0.84 | KMT2A (0.62) | KMT2AMEN1LMNAGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3472133-B1 | PERK INHIBITORS AND USES THEREOF IN TREATING DISEASES ASSOCIATED WITH AGGREGATION-PRONE PROTEINS | UNIV RAMOT (IL) | 2023-10-11 | — | — | EP | disclosed |
| US-20200331865-A1 | PERK INHIBITORS AND USES THEREOF IN TREATING DISEASES ASSOCIATED WITH AGGREGATION-PRONE PROTEINS | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2020-10-22 | — | — | US | disclosed |
| US-10723706-B2 | Perk inhibitors and uses thereof in treating diseases associated with aggregation-prone proteins | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2020-07-28 | — | — | US | disclosed |
| WO-2017216792-A1 | PERK INHIBITORS AND USES THEREOF IN TREATING DISEASES ASSOCIATED WITH AGGREGATION-PRONE PROTEINS | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2017-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331865-A1 | PERK INHIBITORS AND USES THEREOF IN TREATING DISEASES ASSOCIATED WITH AGGREGATION-PRONE PROTEINS | XBP1, HSPA5, HSPA4 | KMT2A 4012/4885MEN1 4546/4885LMNA 2540/4885 |
| US-10723706-B2 | Perk inhibitors and uses thereof in treating diseases associated with aggregation-prone proteins | XBP1, HSPA5, HSPA4 | KMT2A 4012/4885MEN1 4546/4885LMNA 2540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.